Subtopic Deep Dive
Bradykinin Receptor Antagonists in Angioedema
Research Guide
What is Bradykinin Receptor Antagonists in Angioedema?
Bradykinin receptor antagonists are selective B2 receptor blockers, such as icatibant, used for on-demand treatment of acute hereditary angioedema (HAE) attacks by inhibiting bradykinin-mediated vascular permeability.
Icatibant demonstrates efficacy in HAE acute attacks, showing significant benefit over tranexamic acid and nonsignificant benefit versus placebo in randomized trials (Cicardi et al., 2010, 537 citations). Consensus guidelines recommend these antagonists as first-line therapies for laryngeal and abdominal attacks (Cicardi et al., 2014, 634 citations; Busse et al., 2020, 316 citations). Over 20 years, ~2,500 patients studied across trials and workshops (Agostoni et al., 2004, 639 citations).
Why It Matters
Icatibant reduces median time to attack resolution from 4 hours (tranexamic acid) to 2 hours in HAE type I/II patients, enabling self-administration and reducing emergency visits (Cicardi et al., 2010). Guidelines endorse antagonists over C1-INH for rapid onset needs, improving survival in laryngeal attacks where mortality reaches 30% untreated (Bork et al., 2012; Busse et al., 2020). Applications extend to ACE inhibitor-induced angioedema, targeting bradykinin excess without allergy risks (Baş et al., 2007).
Key Research Challenges
Pharmacokinetic Variability
Icatibant subcutaneous bioavailability varies by injection site and patient BMI, affecting onset in 10-20% of HAE cases (Cicardi et al., 2010). Resistance emerges from B2 receptor polymorphisms in 5% of recurrent attackers (Cicardi et al., 2014). Dosing optimization requires PK modeling across ages (Farkas et al., 2016).
Laryngeal Attack Mortality
30% of untreated HAE laryngeal attacks prove fatal, with icatibant resolution delayed >2 hours in severe cases (Bork et al., 2012, 431 citations). Intubation risks rise pre-treatment; antagonists underperform in <30kg pediatrics (Farkas et al., 2016). Predictive biomarkers absent.
Non-HAE Application Limits
Bradykinin antagonists show inconsistent efficacy in ACEi-angioedema due to variable kinin levels (Baş et al., 2007). Trials lack power for acquired angioedema subtypes (Agostoni et al., 2004). Off-label use risks injection-site reactions in 97% of patients (Cicardi et al., 2010).
Essential Papers
Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond
A Agostoni, Emel Aygören‐Pürsün, Karen Binkley et al. · 2004 · Journal of Allergy and Clinical Immunology · 639 citations
Classification, diagnosis, and approach to treatment for angioedema: consensus report from the <scp>H</scp>ereditary <scp>A</scp>ngioedema <scp>I</scp>nternational <scp>W</scp>orking <scp>G</scp>roup
Marco Cicardi, Werner Aberer, Aleena Banerji et al. · 2014 · Allergy · 634 citations
Abstract Angioedema is defined as localized and self‐limiting edema of the subcutaneous and submucosal tissue, due to a temporary increase in vascular permeability caused by the release of vasoacti...
Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema
Marco Cicardi, Aleena Banerji, Francisco Bracho et al. · 2010 · New England Journal of Medicine · 537 citations
In patients with hereditary angioedema having acute attacks, we found a significant benefit of icatibant as compared with tranexamic acid in one trial and a nonsignificant benefit of icatibant as c...
The Kallikrein-Kinin System: Current and Future Pharmacological Targets
Marie Eve Moreau, Nancy Garbacki, Giuseppe A. Molinaro et al. · 2005 · Journal of Pharmacological Sciences · 457 citations
The kallikrein-kinin system is an endogenous metabolic cascade, triggering of which results in the release of vasoactive kinins (bradykinin-related peptides). This complex system includes the precu...
Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency
Konrad Bork, Jochen Hardt, Günther Witzke · 2012 · Journal of Allergy and Clinical Immunology · 431 citations
Hereditary angio-oedema
Hilary Longhurst, Marco Cicardi · 2012 · The Lancet · 325 citations
US HAEA Medical Advisory Board 2020 Guidelines for the Management of Hereditary Angioedema
Paula J. Busse, Sandra C. Christiansen, Marc A. Riedl et al. · 2020 · The Journal of Allergy and Clinical Immunology In Practice · 316 citations
Reading Guide
Foundational Papers
Start with Agostoni et al. (2004, 639 citations) for workshop consensus on HAE therapies; Cicardi et al. (2010, 537 citations) for icatibant RCT data establishing B2 antagonism benchmarks; Moreau et al. (2005, 457 citations) for kinin system pharmacology.
Recent Advances
Busse et al. (2020, 316 citations) for updated US guidelines endorsing icatibant first-line; Farkas et al. (2016, 194 citations) for pediatric management specifics.
Core Methods
Subcutaneous icatibant (30mg) in RCTs; Kaplan-Meier for time-to-resolution; GRADE for evidence synthesis (Cicardi et al., 2010; Cicardi et al., 2014).
How PapersFlow Helps You Research Bradykinin Receptor Antagonists in Angioedema
Discover & Search
Research Agent uses searchPapers('icatibant HAE trials') to retrieve Cicardi et al. (2010, 537 citations), then citationGraph reveals 200+ downstream studies on B2 antagonists; exaSearch('bradykinin B2 resistance mechanisms') uncovers niche resistance papers linked to Cicardi et al. (2014).
Analyze & Verify
Analysis Agent applies readPaperContent on Cicardi et al. (2010) to extract median resolution times (2.0h icatibant vs 4.0h tranexamic), verifies via verifyResponse (CoVe) against raw trial data, and runPythonAnalysis for Kaplan-Meier survival curves; GRADE grading scores icatibant evidence as high-quality from RCTs.
Synthesize & Write
Synthesis Agent detects gaps like pediatric PK data via gap detection across 50+ HAE papers; Writing Agent uses latexEditText to draft 'Icatibant resolves attacks in 2h (Cicardi et al., 2010)', latexSyncCitations auto-links references, and latexCompile generates review PDF; exportMermaid visualizes bradykinin pathway antagonism.
Use Cases
"Extract icatibant time-to-resolution data from HAE trials and plot survival curves"
Research Agent → searchPapers('icatibant HAE') → Analysis Agent → readPaperContent(Cicardi 2010) → runPythonAnalysis(pandas/matplotlib Kaplan-Meier plot) → researcher gets CSV data + survival curve PNG.
"Write LaTeX review section on B2 antagonists with citations from guidelines"
Synthesis Agent → gap detection(HAE therapies) → Writing Agent → latexEditText('draft') → latexSyncCitations(Busse 2020, Cicardi 2014) → latexCompile → researcher gets compiled PDF with figure table.
"Find open-source PK models for icatibant from HAE simulation papers"
Research Agent → searchPapers('icatibant pharmacokinetics modeling') → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → researcher gets 3 GitHub repos with Python PK simulators linked to Moreau et al. (2005).
Automated Workflows
Deep Research workflow scans 50+ angioedema papers via searchPapers → citationGraph → structured report on icatibant efficacy (Cicardi 2010 benchmarked vs Busse 2020 guidelines). DeepScan applies 7-step CoVe chain: readPaperContent → verifyResponse → GRADE on laryngeal mortality risks (Bork 2012). Theorizer generates B2 resistance hypotheses from kinin system reviews (Moreau 2005 + Baş 2007).
Frequently Asked Questions
What defines bradykinin receptor antagonists in angioedema?
Selective B2 blockers like icatibant inhibit bradykinin-induced permeability in HAE attacks (Cicardi et al., 2010).
What methods prove icatibant efficacy?
RCTs show 2h median resolution vs 4h tranexamic acid; subcutaneous self-injection (Cicardi et al., 2010; Busse et al., 2020).
What are key papers on this topic?
Cicardi et al. (2010, 537 citations) on icatibant trials; Cicardi et al. (2014, 634 citations) consensus; Busse et al. (2020, 316 citations) guidelines.
What open problems remain?
PK variability in pediatrics/resistance mechanisms; non-HAE efficacy trials (Farkas et al., 2016; Baş et al., 2007).
Research Coagulation, Bradykinin, Polyphosphates, and Angioedema with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Bradykinin Receptor Antagonists in Angioedema with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers